Trials / Completed
CompletedNCT01859819
Treatment for Advanced B-Cell Lymphoma
Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- New York Medical College · Academic / Other
- Sex
- All
- Age
- 3 Years – 31 Years
- Healthy volunteers
- Not accepted
Summary
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, \[Depocyt®\]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy backbone (Immunochemotherapy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | |
| DRUG | IT Cytarabine |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2020-06-01
- Completion
- 2021-06-01
- First posted
- 2013-05-22
- Last updated
- 2022-10-25
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01859819. Inclusion in this directory is not an endorsement.